日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel

德国代谢功能障碍相关性脂肪性肝炎的诊断和管理:专家共识小组的见解

Kim, Yestle; Rydqvist, Peter; Ramezani, Thomas; Haas, Jennifer S; Bantel, Heike; Buggisch, Peter; Geier, Andreas; Hofmann, Wolf-Peter; Mauss, Stefan; Roeb, Elke; Schattenberg, Jörn M; Simon, Karl-Georg; Stefan, Norbert; Deterding, Katja; Wiegand, Johannes; Pathil, Anita; Tacke, Frank

Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis

代谢功能障碍相关性脂肪性肝炎患者使用胰高血糖素样肽-1受体激动剂相关的医疗保健成本和治疗模式

Tapper, Elliot B; Ryan, Taylor; Zeng, Ni; Carter, Renee; Winer-Jones, Jessamine P; Bonafede, Machaon; Kim, Yestle

Estimating the clinical and healthcare burden of metabolic dysfunction-associated steatohepatitis in England: a retrospective cohort study using routinely collected healthcare data from 2011 to 2020

利用2011年至2020年常规收集的医疗保健数据,对英格兰代谢功能障碍相关脂肪性肝炎的临床和医疗保健负担进行回顾性队列研究

Davidson, Jennifer A; Brewer, Hannah R; Rice, Caoimhe T; Carvalho, Sara J; Kim, Yestle

Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments

代谢功能障碍相关脂肪性肝炎患者健康效用评估:疾病特异性慢性肝病问卷、简表SF-6D和EuroQol EQ-5D工具之间的交叉对照

Younossi, Zobair M; Stepanova, Maria; Kim, Yestle; Dodge, Stephen; Labriola, Dominic; Taub, Rebecca; Nader, Fatema

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

美国代谢功能障碍相关脂肪性肝炎患者皮下注射司美格鲁肽真实世界治疗模式的回顾性研究

Kim, Yestle; Zeng, Ni; Winer-Jones, Jessamine P; Bonafede, Machaon; Lobo, Francis; O'Donnell, John; Ryan, Taylor

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

美国成年人中适合使用瑞美替罗治疗中度至重度肝纤维化非肝硬化性NASH的人群估计

Fishman, Jesse; Kim, Yestle; Charlton, Michael R; Smith, Zachary J; O'Connell, Tom; Bercaw, Eric M

Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients

非酒精性脂肪性肝炎进展为晚期肝病及Medicare患者死亡率

Kim, Yestle; Medicis, Joe; Davis, Matthew; Nunag, Dominic; Gish, Robert

A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol

针对真实临床环境中代谢功能障碍相关性脂肪性肝炎的临床决策支持工具:一项混合方法实施研究方案

Fishman, Jesse; Alexander, Theresa; Kim, Yestle; Kindt, Iris; Mendez, Patricia

Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study

Medicare患者非酒精性脂肪性肝炎疾病进展的相关成本:一项回顾性队列研究

Kim, Yestle; Medicis, Joseph; Davis, Matthew; Nunag, Dominic; Gish, Robert

Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study

代谢功能障碍相关性脂肪性肝炎中肝硬化和肝病进展的成本负担:一项美国队列研究

Fishman, J Collin; Qian, Christina; Kim, Yestle; Rochon, Hannah; Szabo, Shelagh M; Sun, Rosie; Charlton, Michael